Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 3480234, 8 pages
https://doi.org/10.1155/2017/3480234
Research Article

Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease

1Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland
2Department of Physiology, Medical University of Bialystok, Bialystok, Poland
3Department of Infectious Diseases and Hepatology in Bytom, Medical University of Silesia, Katowice, Poland

Correspondence should be addressed to Magdalena Świderska; lp.ude.bmu@aksrediws.aneladgam

Received 13 April 2017; Revised 2 July 2017; Accepted 9 July 2017; Published 30 July 2017

Academic Editor: Partha Mukhopadhyay

Copyright © 2017 Magdalena Świderska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Zacharakis, J. Koskinas, S. Kotsiou et al., “The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(−) hepatitis B infection: association with liver disease progression. A prospective cohort study,” Journal of Hepatology, vol. 49, pp. 884–891, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Fattovich, N. Olivari, M. Pasino, M. D’Onofrio, E. Martone, and F. Donato, “Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years,” Gut, vol. 57, pp. 84–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. R. Brunetto, F. Oliveri, B. Coco et al., “Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study,” Journal of Hepatology, vol. 36, pp. 263–270, 2002. View at Google Scholar
  4. N. Terrault, R. Kim, S. Schalm et al., “Presence of biopsy-proven histologic damage (necroinflammation and fibrosis) is common even when ALT is less than 2xULN in patients with chronic hepatitis B (CHB),” Journal of Hepatology, vol. 46, no. S1, p. S184, 2007. View at Google Scholar
  5. P. Bedossa, D. Dargère, and V. Paradis, “Sampling variability of liver fibrosis in chronic hepatitis C,” Hepatology, vol. 38, pp. 1449–1457, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. N. H. Afdhal, B. R. Bacon, K. Patel et al., “Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study,” Clinical Gastroenterology and Hepatology, vol. 13, pp. 772–779, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Sturm, A. Marlu, P. Arvers, J. P. Zarski, and V. Leroy, “Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C,” Liver International, vol. 33, pp. 428–438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Schattenberg, P. R. Galle, and M. Schuchmann, “Apoptosis in liver disease,” Liver International, vol. 26, pp. 904–911, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. D. Maliken, J. E. Nelson, H. M. Klintworth, M. Beauchamp, M. M. Yeh, and K. V. Kowdley, “Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease,” Hepatology, vol. 57, pp. 1806–1813, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Zhang, Z. Guo, L. Zhang et al., “Maternal immunization promotes the immune response of neonates towards hepatitis B vaccine,” Journal of Viral Hepatitis, vol. 20, pp. 875–881, 2013. View at Google Scholar
  12. M. Luto, J. Jaroszewicz, and R. Flisiak, “Cytokeratin 18 as an indicator of the activity of liver disease,” Polski Merkuriusz Lekarski, vol. 31, pp. 331–334, 2011. View at Google Scholar
  13. H. Bantel, A. Lügering, J. Heidemann et al., “Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury,” Hepatology, vol. 40, pp. 1078–1087, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Sumer, N. Aktug Demir, S. Kölgelier et al., “The clinical significance of serum apoptotic cytokeratin 18 neoepitope M30 (M30 CK-18) and matrix metalloproteinase 2 (MMP-2) levels in chronic hepatitis B patients with cirrhosis,” Hepatitis Monthly, vol. 13, no. 6, article e10106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Micha, J. Cummings, A. Shoemaker et al., “Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer,” Clinical Cancer Research, vol. 14, pp. 7304–7310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Petris, E. Brandén, R. Herrmann et al., “Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer,” European Journal of Cancer, vol. 47, pp. 131–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. G. V. Papatheodoridis, E. Hadziyannis, E. Tsochatzis et al., “Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection,” Gut, vol. 57, pp. 500–506, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. V. Papatheodoridis, E. Hadziyannis, E. Tsochatzis et al., “Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease,” Journal of Clinical Gastroenterology, vol. 44, pp. 87–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Jaroszewicz, B. Calle Serrano, K. Wursthorn et al., “Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV) -infection: a European perspective,” Journal of Hepatology, vol. 52, pp. 514–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. R. Brunetto, F. Oliveri, P. Colombatto et al., “Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers,” Gastroenterology, vol. 139, pp. 483–490, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Martinot-Peignoux, M. Lapalus, T. Asselah, and P. Marcellin, “HBsAg quantification: useful for monitoring natural history and treatment outcome,” Liver International, vol. 34, no. S1, pp. 97–107, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. B. Zeisel, J. Lucifora, W. S. Mason et al., “Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure,” Gut, vol. 64, pp. 1314–1326, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. A. B. Jazwinski, A. J. Thompson, P. J. Clark, S. Naggie, H. L. Tillmann, and K. Patel, “Elevated serum CK-18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis,” Journal of Viral Hepatitis, vol. 19, pp. 278–282, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Parfieniuk-Kowerda, T. W. Lapinski, M. Rogalska-Plonska et al., “Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C,” Liver International, vol. 34, pp. 544–550, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Tabuchi, K. Tomioka, T. Kawakami et al., “Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD),” Journal of Nutritional Science and Vitaminology, vol. 56, pp. 271–278, 2010. View at Google Scholar
  26. H. Bantel, K. John, and K. Schulze-Osthoff, “Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments,” The American Journal of Gastroenterology, vol. 109, pp. 140-141, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. C. B. Bae, S. S. Kim, S. J. Ahn et al., “Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection,” Journal of Clinical Virology, vol. 58, pp. 641–646, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Shi, S. Sun, Y. Liu et al., “Keratin 18 phosphorylation as a progression marker of chronic hepatitis B,” Virology Journal, vol. 7, p. 70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. H. L. Chan, V. W. Wong, A. M. Tse et al., “Serum hepatitis B surface antigen quantitation can reflect hepatitis B. Virus in the liver and predict treatment response,” Clinical Gastroenterology and Hepatology, vol. 5, pp. 1462–1468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Świderska, M. Pawłowska, W. Mazur et al., “Distribution of HBV genotypes in Poland,” Clinical and Experimental Hepatology, vol. 1, pp. 1–4, 2015. View at Google Scholar
  31. A. G. Miamen, H. Dong, and L. R. Roberts, “Immunotherapeutic approaches to hepatocellular carcinoma treatment,” Liver Cancer, vol. 1, no. 3-4, pp. 226–237, 2012. View at Publisher · View at Google Scholar
  32. H. Elalfy, T. Besheer, M. M. Arafa, M. A. El-Hussiny, M. A. El Latif, and S. A. Alsayed, “Caspase-cleaved cytokeratin 18 fragment M30 as a potential biomarker of macrovascular invasion in hepatocellular carcinoma,” Journal of Gastrointestinal Cancer, 2017. View at Publisher · View at Google Scholar
  33. Y. Ngo, Y. Benhamou, V. Thibault et al., “An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load,” PLoS One, vol. 3, no. 7, article e2573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. L. A. Adams, M. Bulsara, E. Rossi et al., “Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection,” Clinical Chemistry, vol. 51, no. 10, pp. 1867–1873, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Joka, K. Wahl, S. Moeller et al., “Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis,” Hepatology, vol. 55, pp. 455–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Reis, J. Wohlschläger, S. Hagemann et al., “(Cleaved) CK-18 serum and tissue expression levels differentiate acute HCV reinfection from acute rejection in liver allografts,” Liver International, vol. 37, no. 3, pp. 905–913, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. S. J. Zheng, S. Liu, M. Liu et al., “Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure,” World Journal of Gastroenterology, vol. 20, no. 9, pp. 2403–2411, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. “EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection,” Journal of Hepatology, 2017. View at Publisher · View at Google Scholar